Literature DB >> 11372746

Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia.

K Ishiga1, T Kawatani, T Suou, F Tajima, H Omura, Y Idobe, H Kawasaki.   

Abstract

We report a case of a 41-year-old man with acute myelogenous leukemia who developed fulminant hepatitis from reactivation of trace hepatitis B virus (HBV) 2 months after complete remission. Although he became positive for HB surface antigen at the onset of fulminant hepatitis, he had been negative for HBV serum markers, and only HBV DNA was detected by polymerase chain reaction (PCR) amplification on admission. The original stocks of serum samples from all blood donors were tested again for HBV DNA by PCR, and all samples were negative. This case demonstrates that testing for HBV DNA by PCR is necessary before chemotherapy, because silent HBV carriers are rare and fulminant hepatitis may be induced by chemotherapy in patients with hematologic malignancies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11372746     DOI: 10.1007/bf02981912

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  14 in total

1.  Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection.

Authors:  I Cacciola; T Pollicino; G Squadrito; G Cerenzia; D Villari; R de Franchis; T Santantonio; S Brancatelli; G Colucci; G Raimondo
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

2.  Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).

Authors:  R Ohno; T Kobayashi; Y Morishima; A Hiraoka; K Imai; N Asoh; K Tsubaki; M Tomonaga; I Takahashi; K Kodera
Journal:  Leukemia       Date:  1992       Impact factor: 11.528

3.  Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus.

Authors:  D Senecal; E Pichon; F Dubois; M Delain; C Linassier; P Colombat
Journal:  Bone Marrow Transplant       Date:  1999-12       Impact factor: 5.483

4.  Hepatitis B virus (HBV) infection and liver disease after allogeneic bone marrow transplantation: a report of 30 cases.

Authors:  A Locasciulli; A Bacigalupo; M T Van Lint; L Chemello; P Pontisso; D Occhini; C Uderzo; H M Shulman; B Portmann; A M Marmont
Journal:  Bone Marrow Transplant       Date:  1990-07       Impact factor: 5.483

5.  Quantitation of hepatitis B virus genomic DNA by real-time detection PCR.

Authors:  A Abe; K Inoue; T Tanaka; J Kato; N Kajiyama; R Kawaguchi; S Tanaka; M Yoshiba; M Kohara
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

6.  Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

Authors:  Y Nakamura; T Motokura; A Fujita; T Yamashita; E Ogata
Journal:  Cancer       Date:  1996-11-15       Impact factor: 6.860

7.  Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal.

Authors:  M Altfeld; J K Rockstroh; M Addo; B Kupfer; I Pult; H Will; U Spengler
Journal:  J Hepatol       Date:  1998-08       Impact factor: 25.083

8.  The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

Authors:  B Rehermann; C Ferrari; C Pasquinelli; F V Chisari
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

9.  Occurrence and management of hepatitis B virus reactivation following kidney transplantation.

Authors:  W Grotz; J Rasenack; T Benzing; H Berthold; T Peters; E Walter; P Schollmeyer; L C Rump
Journal:  Clin Nephrol       Date:  1998-06       Impact factor: 0.975

10.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

View more
  6 in total

Review 1.  Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

Authors:  Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

2.  Occult HBV infection among Egyptian hepatocellular carcinoma patients.

Authors:  Zeinab K Hassan; Mohamed M Hafez; Tarek M Mansor; Abdel Rahman N Zekri
Journal:  Virol J       Date:  2011-03-03       Impact factor: 4.099

3.  Detection of HBV genotypes of tumor tissues and serum by a fluorescence polarization assay in north-western China's hepatocellular carcinoma patients.

Authors:  Jianguo Lu; Weidong Gong; Hong Cheng; Zhiqun Wu; Ding Li; Xiangling Wang; Ping Liang; Ju Zhang
Journal:  Virol J       Date:  2011-07-22       Impact factor: 4.099

4.  High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia.

Authors:  Chien-Yuan Chen; Sheng-Yi Huang; Aristine Cheng; Wen-Chien Chou; Ming Yao; Jih-Luh Tang; Woei Tsay; Wang-Huei Sheng; Hwei-Fang Tien
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 5.  Prevention of Hepatitis B reactivation in the setting of immunosuppression.

Authors:  Venessa Pattullo
Journal:  Clin Mol Hepatol       Date:  2016-06-13

6.  Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan.

Authors:  Chien-Yuan Chen; Feng-Ming Tien; Aristine Cheng; Shang-Yi Huang; Wen-Chien Chou; Ming Yao; Jih-Luh Tang; Hwei-Fang Tien; Wang-Huei Sheng
Journal:  BMC Gastroenterol       Date:  2018-01-08       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.